Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ENTA
- Price
- 7.50
- Stock movement down
- -0.05 (-0.69%)
- Company name
- Enanta Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 152.18M
- Ent value
- 362.78M
- Price/Sales
- 2.25
- Price/Book
- 1.18
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -40.51%
- 3 year return
- -43.60%
- 5 year return
- -32.18%
- 10 year return
- -16.17%
Last updated: 2025-06-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ENTA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.25 |
| Price to Book | 1.18 |
| EV to Sales | 5.36 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 21.19M |
| EPS (TTM) | -5.48 |
| FCF per share (TTM) | -4.56 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 67.64M |
| Gross profit (TTM) | 66.37M |
| Operating income (TTM) | -121.69M |
| Net income (TTM) | -116.05M |
| EPS (TTM) | -5.48 |
| EPS (1y forward) | -4.95 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.13% |
| Operating margin (TTM) | -179.92% |
| Profit margin (TTM) | -171.58% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 37.23M |
| Net receivables | 38.65M |
| Total current assets | 299.85M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 376.65M |
| Accounts payable | 8.00M |
| Short/Current long term debt | 55.47M |
| Total current liabilities | 57.53M |
| Total liabilities | 247.84M |
| Shareholder's equity | 128.81M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -78.76M |
| Capital expenditures (TTM) | 17.95M |
| Free cash flow (TTM) | -96.71M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -90.09% |
| Return on Assets | -30.81% |
| Return on Invested Capital | -89.03% |
| Cash Return on Invested Capital | -74.20% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.36 |
| Daily high | 7.41 |
| Daily low | 6.96 |
| Daily Volume | 184K |
| All-time high | 126.37 |
| 1y analyst estimate | 16.88 |
| Beta | 0.57 |
| EPS (TTM) | -5.48 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ENTA | S&P500 | |
| Current price drop from All-time high | -94.06% | -2.16% |
| Highest price drop | -96.63% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -45.85% | -11.04% |
| Avg time to new high | 41 days | 12 days |
| Max time to new high | 1740 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
152.18M
Marketcap category
Small-cap
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Employees
145
Website
Investor relations
-
SEC filings
CEO
Jay R. Luly
Country
USA
City
Watertown
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page